Intensive course: ‘Model-based drug development: Incorporating population variability into mechani
Venue: Hyatt Fisherman’s Wharf
Location: San Francisco, California, United States
Event Date/Time: May 23, 2011 | End Date/Time: May 27, 2011 |
Registration Date: Apr 21, 2011 | |
Early Registration Date: Feb 18, 2011 |
Description
• Metabolic drug clearance (CL)
• Metabolic drug-drug interactions (DDIs)
• Gut first-pass metabolism
• Oral drug absorption incorporating food effects and the impact of dosage form
• Effect of transporters and enterohepatic recirculation on kinetics and DDIs
• Drug distribution to different organs
• Population variability in drug concentration-time profiles
• Variation in kinetics in specific populations (paediatrics, ethnic groups, various disease populations)
• Pharmacodynamic effects of different compounds
• Time-course of drug in plasma that fits observed clinical data (achieved by combining fitting techniques with IVIVE, PBPK and drug specific in vitro data)
The model-based approach is rapidly being adopted by industry to streamline drug development. These workshops focus on the optimal use of in vitro, in vivo and compound-specific data to simulate and understand drug behaviour in various target populations. This integrated approach informs decisions on the conduct and optimal design of clinical studies with the ultimate aim of improving the quality of submissions for regulatory approval.
The workshops are split into two parts and will be held at the Hyatt Fisherman’s Wharf, San Francisco. Delegates may register for all or part of the course:
Part I: 23rd – 25th May 2011
Part II: 25th – 27th May 2011